| P2093 | author name string | Shingo Miyamoto | |
| | Kazumichi Ando | |
| | Rika Okada | |
| P2860 | cites work | INHIBITION OF CELL DIVISION IN ESCHERICHIA COLI BY ELECTROLYSIS PRODUCTS FROM A PLATINUM ELECTRODE | Q28202030 |
| | FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer | Q29547638 |
| | Management and preparedness for infusion and hypersensitivity reactions | Q30229857 |
| | Use of cisplatin without desensitization after carboplatin hypersensitivity reaction in epithelial ovarian and primary peritoneal cancer | Q30444226 |
| | Clinical features of hypersensitivity reactions to oxaliplatin: a 10-year experience | Q33382153 |
| | Hypersensitivity reactions to intraperitoneal administration of carboplatin in ovarian cancer: the first report of a case | Q33537707 |
| | Single agent carboplatin versus carboplatin plus pegylated liposomal doxorubicin in recurrent ovarian cancer: final survival results of a SWOG (S0200) phase 3 randomized trial | Q33717993 |
| | Management of hypersensitivity to platinum- and taxane-based chemotherapy: cepo review and clinical recommendations | Q33982751 |
| | The diagnosis and management of anaphylaxis practice parameter: 2010 Update | Q34130242 |
| | World allergy organization guidelines for the assessment and management of anaphylaxis | Q34319703 |
| | Hypersensitivity reactions and the utility of oral and intravenous desensitization in patients with gynecologic malignancies. | Q34344864 |
| | Prevention and management of antineoplastic-induced hypersensitivity reactions | Q34417647 |
| | S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial | Q34588472 |
| | Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial | Q34607843 |
| | Risk factors for oxaliplatin-induced hypersensitivity reactions in Japanese patients with advanced colorectal cancer | Q34648284 |
| | Phase III Trial Assessing Bevacizumab in Stages II and III Carcinoma of the Colon: Results of NSABP Protocol C-08 | Q34662825 |
| | Hypersensitivity and idiosyncratic reactions to oxaliplatin | Q35113837 |
| | Decreased hypersensitivity reactions with carboplatin-pegylated liposomal doxorubicin compared to carboplatin-paclitaxel combination: analysis from the GCIG CALYPSO relapsing ovarian cancer trial | Q44131214 |
| | Carboplatin-, oxaliplatin-, and cisplatin-specific IgE: cross-reactivity and value in the diagnosis of carboplatin and oxaliplatin allergy. | Q44270043 |
| | Penicillin allergy and desensitization in serious infections during pregnancy | Q44631301 |
| | Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. | Q44919656 |
| | Carboplatin hypersensitivity: does introduction of skin test and desensitization reliably predict and avoid the problem? A prospective single-center study | Q45022840 |
| | Pegylated liposomal Doxorubicin and Carboplatin compared with Paclitaxel and Carboplatin for patients with platinum-sensitive ovarian cancer in late relapse | Q46082130 |
| | Hypersensitivity and desensitization to antineoplastic agents: outcomes of 189 procedures with a new short protocol and novel diagnostic tools assessment | Q46287048 |
| | Analysis of the pattern of hypersensitivity reactions in patients receiving carboplatin retreatment for recurrent ovarian cancer | Q46406399 |
| | Combination therapy with gemcitabine and carboplatin in recurrent ovarian cancer | Q46445233 |
| | Antigen-IgE desensitization in signal transducer and activator of transcription 6-deficient mast cells by suboptimal doses of antigen | Q46536412 |
| | Allergic-type reactions to oxaliplatin: retrospective analysis of 42 patients | Q46696177 |
| | Cisplatinum rechallenge in relapsed ovarian cancer patients with platinum reinduction therapy and carboplatin hypersensitivity | Q46712987 |
| | Hypersensitivity reactions to oxaliplatin: experience in a single institute | Q46799674 |
| | Death from anaphylaxis to cisplatin: a case report | Q46917031 |
| | Cis-platinum: a new anticancer agent | Q50610869 |
| | Evaluation of basophil CD203c as a predictor of carboplatin-related hypersensitivity reaction in patients with gynecologic cancer. | Q50911737 |
| | Risk factors contributing to the development of carboplatin-related delayed hypersensitivity reactions in Japanese patients with gynecologic cancers. | Q51772362 |
| | Analysis of patients with epithelial ovarian cancer or fallopian tube carcinoma retreated with cisplatin after the development of a carboplatin allergy. | Q52123582 |
| | National study of US emergency department visits for acute allergic reactions, 1993 to 2004. | Q53237542 |
| | Rapid IgE desensitization is antigen specific and impairs early and late mast cell responses targeting FcεRI internalization. | Q53264281 |
| | Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial. | Q53300225 |
| | Hypersensitivity Reactions to Chemotherapeutic Drugs | Q35117323 |
| | The prophylactic conversion to an extended infusion schedule and use of premedication to prevent hypersensitivity reactions in ovarian cancer patients during carboplatin retreatment | Q35205223 |
| | Carboplatin hypersensitivity. | Q36020031 |
| | Subthreshold desensitization of human basophils re-capitulates the loss of Syk and FcεRI expression characterized by other methods of desensitization | Q36052942 |
| | Oxaliplatin-induced severe anaphylactic reactions in metastatic colorectal cancer: case series analysis | Q36316717 |
| | Rapid desensitization for hypersensitivity reactions to chemotherapy agents | Q36529594 |
| | Hypersensitivity reactions related to oxaliplatin (OHP). | Q36671350 |
| | Deleterious BRCA1/2 mutation is an independent risk factor for carboplatin hypersensitivity reactions | Q37111145 |
| | Hypersensitivity reactions to chemotherapy: outcomes and safety of rapid desensitization in 413 cases | Q37172921 |
| | Rapid desensitization induces internalization of antigen-specific IgE on mouse mast cells | Q37213198 |
| | Skin tests in the diagnosis of drug hypersensitivity reactions. | Q37320436 |
| | Acetylsalicylic acid and montelukast block mast cell mediator-related symptoms during rapid desensitization | Q37397059 |
| | Hypersensitivity to oxaliplatin: an investigation of incidence and risk factors, and literature review | Q37402263 |
| | Hypersensitivity to oxaliplatin: clinical features and risk factors. | Q37497459 |
| | Risk stratification for desensitization of patients with carboplatin hypersensitivity: clinical presentation and management | Q37509716 |
| | Allergic reactions to oxaliplatin in a single institute in Japan | Q37531531 |
| | The complex clinical picture of presumably allergic side effects to cytostatic drugs: symptoms, pathomechanism, reexposure, and desensitization | Q37770689 |
| | Acute hypersensitivity reactions to chemotherapy agents: an overview | Q37772926 |
| | Desensitization regimens for drug allergy: state of the art in the 21st century | Q37924898 |
| | IgE and mast cells in allergic disease | Q38007829 |
| | Occupational exposure to anti-cancer drugs: A review of effects of new technology | Q38131440 |
| | Diagnostic tools for hypersensitivity to platinum drugs and taxanes: skin testing, specific IgE, and mast cell/basophil mediators | Q38222050 |
| | Superiority of oxaliplatin and fluorouracil-leucovorin compared with either therapy alone in patients with progressive colorectal cancer after irinotecan and fluorouracil-leucovorin: interim results of a phase III trial | Q39394495 |
| | Germ cell tumors (II). VAB II in metastatic testicular cancer | Q39518935 |
| | A protocol for risk stratification of patients with carboplatin-induced hypersensitivity reactions | Q39685121 |
| | Unique aspects of supportive care using monoclonal antibodies in cancer treatment | Q40414276 |
| | Expanded experience with an intradermal skin test to predict for the presence or absence of carboplatin hypersensitivity | Q40543185 |
| | Hypersensitivity reaction to cisplatin during chemoradiation therapy for gynecologic malignancy | Q40569336 |
| | Oxaliplatin-induced fever and release of IL-6. | Q40612868 |
| | Antigen-specific desensitization of patients allergic to penicillin | Q42243189 |
| | Carboplatin-induced immune hemolytic anemia | Q42552294 |
| | Oxaliplatin-free interval as a risk factor for hypersensitivity reaction among colorectal cancer patients treated with FOLFOX. | Q42780843 |
| | Challenge of mast cells with increasing amounts of antigen induces desensitization | Q42824666 |
| | Characteristics and risk factors of oxaliplatin-related hypersensitivity reactions | Q43055457 |
| | Allergen immunotherapy-induced biphasic systemic reactions: incidence, characteristics, and outcome: a prospective study | Q43167472 |
| | Oxaliplatin-induced allergic reaction in patients with colorectal cancer in Japan | Q43255219 |
| | Fluorouracil versus combination of irinotecan plus cisplatin versus S-1 in metastatic gastric cancer: a randomised phase 3 study | Q43264239 |
| | Idiosyncratic reaction after oxaliplatin infusion | Q43542629 |
| | Hypersensitivity reactions to carboplatin administration are common but not always severe: a 10-year experience | Q43723588 |
| | Effectiveness of oxaliplatin desensitization protocols | Q44080416 |
| P433 | issue | 9 | |
| P304 | page(s) | 795-804 | |
| P577 | publication date | 2015-06-07 | |
| P1433 | published in | Japanese Journal of Clinical Oncology | Q2231629 |
| P1476 | title | Platinum hypersensitivity and desensitization | |
| P478 | volume | 45 | |